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Introduction
Occult hepatitis B virus infection (OBI) is a clinical 
form of hepatitis B which in spite of an undetectable 
amount of the hepatitis B surface antigen (HBsAg) 
in the patient’s serum, the hepatitis B virus (HBV) 
DNA is obviously visible in the patient’s serum (1-3). 
This type of hepatitis is one of the main challenges 
for blood transfusion services and even if all of the 
donated blood and blood components are screened 
for HBsAg, some cases of post-transfusion hepatitis 
B have been reported (4). In most instances, the main 
cause of post transfusion hepatitis B infection is OBI 
(5), which we found in our previous investigations in 
Isfahan and Kerman, the two central provinces of 
Iran (5, 6). However, the mechanism(s) responsible 
for the progression of OBI have yet to be clarified 
but  some  investigators  have  suggested  the  key 
roles of genetic and immunological parameters in 
the  resistance  of  some  individuals  as  well  as  the 
susceptibility of others (7, 8).
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Background and Aims:  Occult hepatitis B infected (OBI) patients can not completely eradicate hepatitis B virus-DNA 
(HBV-DNA) from their liver and peripheral blood. The main aim of this study was to investigate the Interleukin (IL)-10 
and IL-17A serum levels in patients suffering from OBI.
Material and Methods: In this observational study, plasma samples of 3700 blood donors were tested for hepatitis B 
surface antigen (HBsAg) and antibodies to the hepatitis B core antigen (anti-HBc), using enzyme-linked immunosorbent 
assay (ELISA). The HBsAg-/anti-HBc+ samples were selected and screened for HBV-DNA, using the polymerase chain 
reaction (PCR). HBV-DNA positive samples were assigned as OBI cases and IL-10 and IL-17 serum levels were detected 
using ELISA.
Results: The results demonstrated that, 352 (9.5%) out of 3700 blood samples were HBsAg-/anti-HBc+ and HBV-DNA 
was detected in 57/352 (16.1%) of the HBsAg-/anti-HBc+ samples. Our results showed that the IL-10 and IL-17A serum 
levels increased significantly in the OBI cases in comparison to the controls (P < 0.001).
Conclusions: According to the results of this study the higher level of IL-10 production may suppress the functioning of 
the immune system against HBV in OBI patients. The elevated IL-17A serum level also indicates a long period of infection 
in the patients observed. 
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  In  the  immune  system,  cytokines  play  an 
important role in appropriate immune response to 
viral infections  (9). Interleukin (IL)-10 is the main 
cytokine  in  the  regulation  of  cellular  immunity 
against  viral  infections,  which  is  produced  by  T 
helper 2 (TH2) and T regulatory lymphocytes (10). 
IL-10 has potent inhibitory effects on some parts 
of the immune system, especially on cell-mediated 
immune  responses  (10).  Therefore,  alterations  in 
this cytokine enable the immune system to reduce 
its eligible immune response against viral infections 
(10, 11). Previous studies showed that IL-17A plays a 
crucial role in chronic infection by means of several 
mechanisms (12, 13). For example, IL-17A upregulates 
anti-apoptosis molecules in hepatocytes (12), and in 
fact, increases the survival of the HBV reservoir. IL-
17A also prevents target cell destruction by means 
of cell-mediated immunity (12). Accordingly, the aim 
of this study was to examine the IL-10 and IL-17A 
serum levels in OBI patients in order to find out the 
mechanism(s) involved in the pathogenesis of the 
disorder. 
Material and Methods
Subjects
Peripheral  blood  samples  were  collected  from 
3700  volunteer  blood  donors  at  the  Rafsanjan 
Blood  Transfusion  Services,  Kerman,  Iran  in 
ethylenediaminetetraacetic acid (EDTA) pre-coated 
5.5 ml tubes. The samples were centrifuged at 370×g 
for 4 minutes. All of the sera were separated within 
24  hours  following  their  collection.  If  necessary, 
serum samples were stored at –20ºC for a maximum 
of 2 months or at -70ºC (for longer periods) for 
further use. For the analysis of polymorphisms, a 
2 ml sample was collected from patients with OBI 
(57 cases) and from one hundred healthy controls 
(HBsAg-/HBV-DNA-/ antibodies to the hepatitis B 
core antigen positive [anti-HBc+]). This study was 
approved  by  the  ethical  committee  of  Rafsanjan 
University of Medical Sciences. 
NB: all of the participants in this study filled out 
and signed the informed consent form which was 
designed with the aims and objectives of the study 
in mind. 
Detection of serological HBV markers 
The  HBsAg  screening  tests  were  performed 
by  enzyme-linked  immunosorbent  assay  (ELISA) 
(Behring, Germany). The antibodies to the hepatitis 
B  core  antigen  (anti-HBc)  screening  test  was 
also  performed  by  a  manual  microplate  enzyme 
immunoassay,  using  a  commercial  anti-HBc  kit 
(RADIM, Italy). The present method is based on 
a competitive enzyme immunoassay (EIA). All of 
the  samples  were  also  screened  by  using  ELISA 
(RADIM,  Italy)  for  possible  hepatitis  C  virus 
(HCV) and human immunodeficiency virus (HIV) 
infections.
HBV- DNA Extraction from plasma samples 
Viral DNA was purified from 200 μl of plasma 
samples. Briefly, each plasma sample was incubated 
at 72ºC for 10 minutes and then cooled down to 4ºC 
for 5 minutes in 200μl proteinase K (200 μg/ml). 
Following phenol/chloroform extraction (1:1), the 
viral DNA was precipitated with ethanol and the 
pellet  was  re-dissolved  in  DNase  free,  deionized 
water and stored at –20ºC for further use.
HBV-DNA PCR and Gel Electrophoresis 
To  amplify  the  S  gene  of  HBV-DNA  a  PCR 
reaction mixture was made by the addition of the 
following reagents to a 0.2 ml micocentrifuge tube on 
ice: 2.5 μl of Taq DNA polymerase buffer (10x), 0.5 
μl of MgCl2 (a stock concentration 1.5 mM), 0.5 μl 
of each dNTP [(dATP, dCTP, dGTP, dTTP) a stock 
concentration of 10 mM], 1 μl of each primer pair 
(stock concentration of 25 ng/μl), 5 μl of prepared 
DNA and sterile double distilled water to a final 
volume of 25 μl. The sequence of primers was as 
follows: F: 5`-TCGTGGTGGACTTCTCTC-3` and 
R:  5`-ACAGTGGGGGAAAGCCC-3`  The  PCR 
thermocycler was run with the following program: 
one  cycle  at  93°C  for  2  mins,  93°C  for  1  min 
(denaturation), 1 min at 55°C (annealing), 72°C for 
40 sec (elongation) followed by 30 cycles at 93ºC for 
20 sec, 55ºC for 20 sec and 72ºC for 40 sec. During 
the last 45 seconds of the first stage, 0.3 µl of Taq 
DNA polymerase was added to the mixture. 
The HBV genome was purchased from Cinnagen-
Iran  and  used  as  the  positive  control.  The  PCR 
product (10 μl) was run on a 2% agarose gel after 
adding 4 μl of loading buffer. The presence of a 
500bp fragment indicated a positive result. 
Parallel to the samples, a 100bp DNA ladder was 
also run to estimate the molecular size of the DNA 
fragments.  The  current  technique  can  detect  100 
copies per microliter. 
Detection of the cytokine serum level
The  IL-10  and  IL-17A  serum  levels  were 
measured using ELISA (eBioscience, ESP) in both 
patients  and  healthy  controls,  immediately  after 
blood collection. Assays were performed according 
to the manufacturer’s guidelines. The sensitivity of 
kits was 2 pg/ml and the coefficient variation (CV) 
for inter- or intra-assay was found to confirm the Hepatitis Monthly, Winter 2010; 10(1): 31-35
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assessment reliability. 
Liver enzymes evaluation
serum  glutamic-pyruvic  transaminase  (SGPT), 
serum glutamic oxaloacetic transaminase (SGOT), 
direct and total bilirobin and alkaline phosphatase 
(ALP) of OBI patients were measured using MAN 
Ltd kits, Iran.
Statistical analysis
The  differences  in  variables  were  analyzed 
by student t-tests. P values of less than 0.05 were 
considered significant.
Results
This  study  was  performed  on  3700  collected 
blood samples at the Rafsanjan Blood Transfusion 
Services. All of the samples were found to be negative 
for  HBsAg,  antibodies  to  HCV  (anti-HCV),  and 
antibodies to HIV (anti-HIV). Out of 3700 samples, 
352 (9.5%) cases were found to be positive for anti-
HBc; HBV-DNA was detected in 57/352 (16.1% 
of HBsAg negative but anti-HBc positive) of them. 
Results of this study indicated that the HBV-DNA 
was detectable in 16.1 % of HBsAg negative but 
anti-HBc positive samples collected, which is 1.54% 
(57/3700) of the total collected samples.
Our results showed that there was no significant 
difference between groups with regard to age, sex and 
socio-economic condition (Table 1). Socio-economic 
condition was measured by level of education and 
by monthly income. All of the samples were also 
negative for HIV and HCV antibodies. 
We found that the IL-10 serum level was 15.05 
± 1.1 pg/ml and 10.2 ± 1.0 pg/ml in OBI patients 
and in the healthy controls, respectively. Statistical 
analysis showed that there was a significant difference 
between the two groups (P < 0.001). 
We  also  showed  that  there  was  a  significant 
increase in the IL-17A serum level (12.48 ± 2.00 
pg/ml) in OBI patients in comparison to healthy 
controls  (4.43  ±  0.54  pg/ml).  Statistical  analysis 
showed  a  significant  difference  between  the  two 
groups (P < 0.001).
The serum levels of ALT, AST, direct and total 
bilirubin were 24U/L, 30U/L, 0.2 mg/dl and 1.2 mg/
dl, respectively, while the serum level of ALP was 23 
U/L, SGOT was 28 U/L, direct bilirubin was 0.15 
mg/dl and total bilirubin was 1.1 mg/dl in healthy 
controls. Statistical analysis showed that there was no 
significant difference between the two groups with 
reference to the above parameters (P > 0. 1).
Discussion
It has been reported that in chronic viral infections, 
the pattern of cytokine expression may have some 
important modifications (14). It is not well defined 
why OBI patients are unable to completely overcome 
viral contamination.However, it seems that cytokines 
play a key role in the clearance of HBV; and several 
studies indicated that NK cells and cytotoxic T cells 
(the two important cells in cellular immunity) depend 
on cytokine balance to function at their best. (15, 16). 
Therefore, this study was aimed at determining the 
IL-10 serum level as a cytokine suppressor of cellular 
immunity and IL-17A as a chronic disease inducer. 
Our results showed that the IL-10 and IL-17A serum 
levels are significantly higher in OBI patients than in 
the controls. Therefore, based on our results it can 
be concluded that a higher IL-10 level can suppress 
immune  responses  to  HBV  infection  in  OBI 
patients. On the other hand, IL-17A upregulates anti-
apoptosis molecules in hepatocytes (12), thus leading 
to increased longevity of the HBV reservoir. To our 
knowledge, this is the first study that has been carried 
out to evaluate the serum levels of these cytokines in 
OBI patients. However, in a study, Bozkaya H et al., 
showed that there was a significant increase in the 
IL-10 serum level in chronic HBV infection among 
the Turkish population (10). An elevated production 
of IL-10 by dendritic cells in chronic HBV infected 
patients has also been reported by Wang et al., (17). 
Fan XG et al., also showed a significant increase in 
the IL-10 serum level in chronic HCV infection (18). 
On the other hand, our previous study showed 
that  the  IL-12  serum  level  did  not  increase  in 
patients  with  OBI  (19);  thus  it  can  be  concluded 
that these patients are unable to express a sufficient 
concentration of IL-12 for HBV clearance and this 
may be related to the antagonistic effects of IL-10 
in these patients. Interestingly, the previous study 
showed that patients with chronic HBV infection 
Table 1. Demographic and socioeconomic conditions of 
occult hepatitis B virus-infected patient and controls.
Variant Healthy Control Patient P-value
Age 28 ± 8 28 ± 6 P > 0.3
Sex
Female 3 (3%) 2 (3.5%) P > 0.2
Male 97 (97.8%) 55 (96.5%) P > 0.19
Socio-Economic Status
Weak 22 (22%) 12 (21%) P > 0.1
Medium 47 (47%) 28 (49%) P > 0.1
High 31 (31%) 17 (30%) P > 0.1Hepatitis Monthly, Winter 2010; 10(1): 31-35
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suffer from defective functioning of the dendritic 
cells, which may be associated with the inability of 
efficient presentation of HBV antigens to the host 
immune  system  for  the  eradication  of  HBV  (17). 
This  property  of  dendritic  cells  in  chronic  HBV 
infection  probably  is  associated  with  an  elevated 
IL-10 level. Xu Y et al., have reported that IL-17A 
protein  and  mRNA  levels  were  increased  in  liver 
injuries following chronic HBV infection, cirrhosis 
and  hepatocarcinoma  (13).  In  agreement  with  our 
study,  an  elevated  IL-17  A  serum  level  in  HBV 
infected patients was also shown by Qin LY and 
colleagues (20). Other studies have also demonstrated 
that there was an increase in the IL-6 serum level 
as an inducer of Th17 clonal expansion in HBV-
infected patients (21-23). However, some studies have 
reported an enhanced level of IL-17A in other viral 
infections (24, 25) but as far as we know this is the 
first reported in OBI. Investigators are suggesting 
that the circulating cytokine profile in HBV infection 
is related to the replication level of the virus and to 
the activity of liver disease. Based on this concept 
that the HBV replication level is very low and liver 
disease is relatively silent in OBI patients, it probably 
could be concluded that the immune system tends 
to be unresponsive to HBV. The IL-10 serum level 
may increase to suppress immune responses to HBV, 
while  an  elevated  IL-17A  level  causes  increased 
hepatocyte survival. 
Finally,  due  to  the  complexity  of  OBI,  other 
aspects of the disease need to be examined and a 
recommended  future  task  for  investigators  would 
be  to  investigate  cytokine  expression  and  the 
polymorphisms of other important related cytokines 
and their receptors, at the level of both protein and 
mRNA in OBI patients.
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